MSH2 and Lynch syndrome: Specifically, MSH2 mutations have been linked to small bowel cancer, although the underlying mechanism remains unclear.29) ICIs are highly effective in Lynch syndrome-associated colorectal cancers,30) and similar benefits may extend to duodenal cancer, although further studies are needed.